| Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver B Costa-Silva, NM Aiello, AJ Ocean, S Singh, H Zhang, BK Thakur, ... Nature cell biology 17 (6), 816-826, 2015 | 2591 | 2015 |
| Organoid profiling identifies common responders to chemotherapy in pancreatic cancer H Tiriac, P Belleau, DD Engle, D Plenker, A Deschênes, TDD Somerville, ... Cancer discovery 8 (9), 1112-1129, 2018 | 779 | 2018 |
| Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma AB Siegel, EI Cohen, A Ocean, D Lehrer, A Goldenberg, JJ Knox, H Chen, ... Journal of clinical oncology: official journal of the American Society of …, 2008 | 596 | 2008 |
| Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer A Bardia, IA Mayer, JR Diamond, RL Moroose, SJ Isakoff, AN Starodub, ... Journal of Clinical Oncology 35 (19), 2141, 2017 | 374 | 2017 |
| First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors AN Starodub, AJ Ocean, MA Shah, MJ Guarino, VJ Picozzi Jr, LT Vahdat, ... Clinical Cancer Research 21 (17), 3870-3878, 2015 | 274 | 2015 |
| Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies AJ Ocean, LT Vahdat Supportive Care in Cancer 12, 619-625, 2004 | 253 | 2004 |
| Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric … MA Shah, YY Janjigian, R Stoller, S Shibata, M Kemeny, S Krishnamurthi, ... Journal of clinical oncology 33 (33), 3874-3879, 2015 | 204 | 2015 |
| Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach K Carlson, AJ Ocean Clinical breast cancer 11 (2), 73-81, 2011 | 178 | 2011 |
| Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics AJ Ocean, AN Starodub, A Bardia, LT Vahdat, SJ Isakoff, M Guarino, ... Cancer 123 (19), 3843-3854, 2017 | 172 | 2017 |
| Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket … A Bardia, WA Messersmith, EA Kio, JD Berlin, L Vahdat, GA Masters, ... Annals of Oncology 32 (6), 746-756, 2021 | 169 | 2021 |
| Therapy of advanced non–small-cell lung cancer with an SN-38-anti-trop-2 drug conjugate, sacituzumab govitecan RS Heist, MJ Guarino, G Masters, WT Purcell, AN Starodub, L Horn, ... Journal of Clinical Oncology 35 (24), 2790-2797, 2017 | 150 | 2017 |
| Therapy of small cell lung cancer (SCLC) with a topoisomerase-i–inhibiting antibody–drug conjugate (ADC) targeting trop-2, sacituzumab govitecan JE Gray, RS Heist, AN Starodub, DR Camidge, EA Kio, GA Masters, ... Clinical Cancer Research 23 (19), 5711-5719, 2017 | 129 | 2017 |
| Fractionated radioimmunotherapy with 90Y‐clivatuzumab tetraxetan and low‐dose gemcitabine is active in advanced pancreatic cancer A phase 1 trial AJ Ocean, KL Pennington, MJ Guarino, A Sheikh, T Bekaii‐Saab, ... Cancer 118 (22), 5497-5506, 2012 | 103 | 2012 |
| Sacituzumab govitecan, a novel antibody–drug conjugate, in patients with metastatic platinum-resistant urothelial carcinoma B Faltas, DM Goldenberg, AJ Ocean, SV Govindan, F Wilhelm, ... Clinical Genitourinary Cancer 14 (1), e75-e79, 2016 | 101 | 2016 |
| Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation M Papaspyridonos, I Matei, Y Huang, M do Rosario Andre, ... Nature communications 6 (1), 6840, 2015 | 98 | 2015 |
| Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 2018; 8: 1112–1129. doi: 10.1158/2159-8290 H Tiriac, P Belleau, DD Engle, D Plenker, A Deschênes, TDD Somerville, ... CD-18-0349.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 98 | |
| Chemotherapy dose intensity predicted by baseline nutrition assessment in gastrointestinal malignancies: a multicentre analysis KA Klute, J Brouwer, M Jhawer, H Sachs, A Gangadin, A Ocean, E Popa, ... European Journal of Cancer 63, 189-200, 2016 | 67 | 2016 |
| Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein JD Schwartz, M Schwartz, D Lehrer, E Cohen, M Sung, M Kinkhabwala, ... Journal of Clinical Oncology 24 (18_suppl), 4144-4144, 2006 | 67 | 2006 |
| Phase I study of epigenetic priming with azacitidine prior to standard neoadjuvant chemotherapy for patients with resectable gastric and esophageal adenocarcinoma: evidence of … BJ Schneider, MA Shah, K Klute, A Ocean, E Popa, N Altorki, ... Clinical Cancer Research 23 (11), 2673-2680, 2017 | 60 | 2017 |
| Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma AP Lam, JA Sparano, V Vinciguerra, AJ Ocean, P Christos, H Hochster, ... American journal of clinical oncology 33 (2), 121-124, 2010 | 54 | 2010 |
